2021
The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective
Sessa C, Cortes J, Conte P, Cardoso F, Choueiri T, Dummer R, Lorusso P, Ottmann O, Ryll B, Mok T, Tempero M, Comis S, Oliva C, Peters S, Tabernero J. The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective. ESMO Open 2021, 7: 100339. PMID: 34953404, PMCID: PMC8608656, DOI: 10.1016/j.esmoop.2021.100339.Peer-Reviewed Original ResearchConceptsInnovative clinical trialsClinical trialsOncology clinical trialsOncology clinical researchClinical researchCancer careClinical trial stakeholdersTrial stakeholdersNew treatmentsPatient accessCancer clinical trialsCOVID-19COVID-19 pandemicNew trial designsFaster patient accessWorldwide clinical trialsClinical trial objectivesOncology expertsOutcome dataTrial designTrial objectivesTrialsRecent dataCareInternational panel
2014
Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.
Maitland M, Ou S, Tolcher A, LoRusso P, Bahceci E, Ball H, Park J, Yuen G, Pesco Koplowitz L, Li T. Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design. Journal Of Clinical Oncology 2014, 32: 2624-2624. DOI: 10.1200/jco.2014.32.15_suppl.2624.Peer-Reviewed Original Research